Gengos Andrew 4
4 · Terns Pharmaceuticals, Inc. · Filed Jun 30, 2025
Insider Transaction Report
Form 4
Gengos Andrew
Chief Financial Officer
Transactions
- Purchase
Common Stock
2025-06-27$3.93/sh+5,000$19,650→ 25,000 total - Purchase
Common Stock
2025-06-27$3.93/sh+5,000$19,634→ 20,000 total